TY - JOUR AU - Torre, L. A. AU - Bray, F. AU - Siegel, R. L. PY - 2015 DA - 2015// TI - Global cancer statistics, 2012 JO - CA Cancer J Clin VL - 65 UR - https://doi.org/10.3322/caac.21262 DO - 10.3322/caac.21262 ID - Torre2015 ER - TY - JOUR AU - Leonardi, G. C. AU - Candido, S. PY - 2012 DA - 2012// TI - Cervello, et al. the tumor microenvironment in hepatocellular carcinoma (review) JO - Int J Oncol VL - 40 ID - Leonardi2012 ER - TY - JOUR AU - Eggert, T. AU - Greten, T. F. PY - 2017 DA - 2017// TI - Tumor regulation of the tissue environment in the liver JO - Pharmacol Ther VL - 173 UR - https://doi.org/10.1016/j.pharmthera.2017.02.005 DO - 10.1016/j.pharmthera.2017.02.005 ID - Eggert2017 ER - TY - JOUR AU - Yi, Y. AU - He, H. W. AU - Wang, J. X. PY - 2013 DA - 2013// TI - The functional impairment of HCC-infiltrating gammadelta T cells, partially mediated by regulatory T cells in a TGF beta- and IL-10-dependent manner JO - J Hepatol VL - 58 UR - https://doi.org/10.1016/j.jhep.2012.12.015 DO - 10.1016/j.jhep.2012.12.015 ID - Yi2013 ER - TY - JOUR AU - Wu, K. AU - Ding, J. AU - Chen, C. PY - 2012 DA - 2012// TI - Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development JO - Hepatology. VL - 56 UR - https://doi.org/10.1002/hep.26007 DO - 10.1002/hep.26007 ID - Wu2012 ER - TY - JOUR AU - Brower, V. PY - 2015 DA - 2015// TI - Checkpoint Blockade Immunotherapy for Cancer Comes of Age JO - JNCI Journal of the National Cancer Institute VL - 107 UR - https://doi.org/10.1093/jnci/djv069 DO - 10.1093/jnci/djv069 ID - Brower2015 ER - TY - JOUR AU - Greten, T. i. m. F. AU - Sangro, B. r. u. n. o. PY - 2018 DA - 2018// TI - Targets for immunotherapy of liver cancer JO - Journal of Hepatology VL - 68 UR - https://doi.org/10.1016/j.jhep.2017.09.007 DO - 10.1016/j.jhep.2017.09.007 ID - Greten2018 ER - TY - JOUR AU - Hato, T. AU - Goyal, L. AU - Greten, T. F. PY - 2014 DA - 2014// TI - Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions JO - Hepatology. VL - 60 UR - https://doi.org/10.1002/hep.27246 DO - 10.1002/hep.27246 ID - Hato2014 ER - TY - JOUR AU - Hu, J. AU - Yan, J. AU - Rao, G. PY - 2014 DA - 2014// TI - The duality of Fgl2—secreted immune checkpoint regulator versus membrane-associated procoagulant: therapeutic potential and implications JO - Int Rev Immunol VL - 35 ID - Hu2014 ER - TY - JOUR AU - Chan, C. W. AU - Kay, L. S. AU - Khadaroo, R. G. PY - 2003 DA - 2003// TI - Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells JO - J Immunol VL - 170 UR - https://doi.org/10.4049/jimmunol.170.8.4036 DO - 10.4049/jimmunol.170.8.4036 ID - Chan2003 ER - TY - JOUR AU - Liu, H. AU - Shalev, I. AU - Manuel, J. PY - 2008 DA - 2008// TI - The FGL2-FcgammaRIIB pathway: a novel mechanism leading to immunosuppression JO - Eur J Immunol VL - 38 UR - https://doi.org/10.1002/eji.200838338 DO - 10.1002/eji.200838338 ID - Liu2008 ER - TY - JOUR AU - Shalev, I. AU - Liu, H. AU - Koscik, C. PY - 2008 DA - 2008// TI - Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis JO - J Immunol VL - 180 UR - https://doi.org/10.4049/jimmunol.180.1.249 DO - 10.4049/jimmunol.180.1.249 ID - Shalev2008 ER - TY - JOUR AU - Bartczak, A. AU - Zhang, J. AU - Adeyi, O. PY - 2017 DA - 2017// TI - Overexpression of fibrinogen-like protein 2 protects against T cell-induced colitis JO - World J Gastroenterol VL - 23 UR - https://doi.org/10.3748/wjg.v23.i15.2673 DO - 10.3748/wjg.v23.i15.2673 ID - Bartczak2017 ER - TY - JOUR AU - Shalev, I. AU - Wong, K. M. AU - Foerster, K. PY - 2009 DA - 2009// TI - The novel CD4+CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis JO - Hepatology. VL - 49 UR - https://doi.org/10.1002/hep.22684 DO - 10.1002/hep.22684 ID - Shalev2009 ER - TY - STD TI - Yan J, Kong LY, Hu J, et al. FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas. J Natl Cancer Inst. 2015;107. https://doi.org/10.1093/jnci/djv137. ID - ref15 ER - TY - JOUR AU - Zhu, Y. AU - Zhang, L. AU - Zha, H. PY - 2017 DA - 2017// TI - Stroma-derived fibrinogen-like protein 2 activates cancer-associated fibroblasts to promote tumor growth in lung cancer JO - Int J Biol Sci VL - 13 UR - https://doi.org/10.7150/ijbs.19398 DO - 10.7150/ijbs.19398 ID - Zhu2017 ER - TY - JOUR AU - Tong, H. AU - Ba, N. AU - Hoan, N. X. PY - 2018 DA - 2018// TI - Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases JO - BMC Infect Dis VL - 18 UR - https://doi.org/10.1186/s12879-018-3473-2 DO - 10.1186/s12879-018-3473-2 ID - Tong2018 ER - TY - JOUR AU - Sun, Y. AU - Xi, D. AU - Ding, W. PY - 2014 DA - 2014// TI - Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma JO - Hepatol Int VL - 8 UR - https://doi.org/10.1007/s12072-014-9568-y DO - 10.1007/s12072-014-9568-y ID - Sun2014 ER - TY - JOUR AU - Liu, H. AU - Yang, P. S. AU - Zhu, T. PY - 2013 DA - 2013// TI - Characterization of fibrinogen-like protein 2 (FGL2): monomeric FGL2 has enhanced immunosuppressive activity in comparison to oligomeric FGL2 JO - Int J Biochem Cell Biol VL - 45 UR - https://doi.org/10.1016/j.biocel.2012.10.014 DO - 10.1016/j.biocel.2012.10.014 ID - Liu2013 ER - TY - JOUR AU - Manning, B. D. AU - Cantley, L. C. PY - 2007 DA - 2007// TI - AKT/PKB signaling: navigating downstream JO - Cell VL - 129 UR - https://doi.org/10.1016/j.cell.2007.06.009 DO - 10.1016/j.cell.2007.06.009 ID - Manning2007 ER - TY - JOUR AU - Du, K. AU - Montminy, M. PY - 1998 DA - 1998// TI - CREB is a regulatory target for the protein kinase Akt/PKB JO - J Biol Chem VL - 273 UR - https://doi.org/10.1074/jbc.273.49.32377 DO - 10.1074/jbc.273.49.32377 ID - Du1998 ER - TY - JOUR AU - Coulthard, L. R. AU - White, D. E. AU - Jones, D. L. PY - 2009 DA - 2009// TI - p38(MAPK): stress responses from molecular mechanisms to therapeutics JO - Trends Mol Med VL - 15 UR - https://doi.org/10.1016/j.molmed.2009.06.005 DO - 10.1016/j.molmed.2009.06.005 ID - Coulthard2009 ER - TY - JOUR AU - Zarubin, T. AU - Han, J. PY - 2005 DA - 2005// TI - Activation and signaling of the p38 MAP kinase pathway JO - Cell Res VL - 15 UR - https://doi.org/10.1038/sj.cr.7290257 DO - 10.1038/sj.cr.7290257 ID - Zarubin2005 ER - TY - JOUR AU - Kim, E. K. AU - Choi, E. J. PY - 1802 DA - 1802// TI - Pathological roles of MAPK signaling pathways in human diseases JO - Biochim Biophys Acta VL - 2010 ID - Kim1802 ER - TY - JOUR AU - Rubinfeld, H. AU - Seger, R. PY - 2004 DA - 2004// TI - The ERK cascade as a prototype of MAPK signaling pathways JO - Methods Mol Biol VL - 250 ID - Rubinfeld2004 ER - TY - JOUR AU - Palucka, A. K. AU - Coussens, L. M. PY - 2016 DA - 2016// TI - The basis of oncoimmunology JO - Cell. VL - 164 UR - https://doi.org/10.1016/j.cell.2016.01.049 DO - 10.1016/j.cell.2016.01.049 ID - Palucka2016 ER - TY - JOUR AU - Park, J. AU - Kwon, M. AU - Shin, E. C. PY - 2016 DA - 2016// TI - Immune checkpoint inhibitors for cancer treatment JO - Arch Pharm Res VL - 39 UR - https://doi.org/10.1007/s12272-016-0850-5 DO - 10.1007/s12272-016-0850-5 ID - Park2016 ER - TY - JOUR AU - Kudo, M. PY - 2017 DA - 2017// TI - Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials JO - Oncology. VL - 92 UR - https://doi.org/10.1159/000451016 DO - 10.1159/000451016 ID - Kudo2017 ER - TY - JOUR AU - Nimmerjahn, F. AU - Jeffrey, V. R. PY - 2008 DA - 2008// TI - Fcγ receptors as regulators of immune responses JO - Nat Rev Immunol VL - 8 UR - https://doi.org/10.1038/nri2206 DO - 10.1038/nri2206 ID - Nimmerjahn2008 ER - TY - JOUR AU - Ardeshna, K. M. AU - Pizzey, A. R. AU - Devereux, S. PY - 2000 DA - 2000// TI - The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells JO - Blood. VL - 96 ID - Ardeshna2000 ER - TY - JOUR AU - Park, D. AU - Lapteva, N. AU - Seethammagari, M. PY - 2006 DA - 2006// TI - An essential role for Akt1 in dendritic cell function and tumor immunotherapy JO - Nat Biotechnol VL - 24 UR - https://doi.org/10.1038/nbt1262 DO - 10.1038/nbt1262 ID - Park2006 ER - TY - JOUR AU - Clement, M. AU - Fornasa, G. AU - Guedj, K. PY - 2014 DA - 2014// TI - CD31 is a key co-inhibitory receptor in the development of immunogenic dendritic cells JO - Proc Natl Acad Sci U S A VL - 111 UR - https://doi.org/10.1073/pnas.1314505111 DO - 10.1073/pnas.1314505111 ID - Clement2014 ER - TY - JOUR AU - Teymouri, M. AU - Pirro, M. AU - Fallarino, F. PY - 2018 DA - 2018// TI - IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases JO - Int J Cancer VL - 143 UR - https://doi.org/10.1002/ijc.31382 DO - 10.1002/ijc.31382 ID - Teymouri2018 ER - TY - JOUR AU - Wang, Z. AU - Liu, J. Q. AU - Liu, Z. PY - 2013 DA - 2013// TI - Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis JO - J Immunol VL - 190 UR - https://doi.org/10.4049/jimmunol.1202535 DO - 10.4049/jimmunol.1202535 ID - Wang2013 ER - TY - JOUR AU - Turnis, M. E. AU - Sawant, D. V. AU - Szymczak-Workman, A. L. PY - 2016 DA - 2016// TI - Interleukin-35 limits anti-tumor immunity JO - Immunity. VL - 44 UR - https://doi.org/10.1016/j.immuni.2016.01.013 DO - 10.1016/j.immuni.2016.01.013 ID - Turnis2016 ER - TY - JOUR AU - Fu, Y. P. AU - Yi, Y. AU - Cai, X. Y. PY - 2016 DA - 2016// TI - Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection JO - Br J Cancer VL - 114 UR - https://doi.org/10.1038/bjc.2016.47 DO - 10.1038/bjc.2016.47 ID - Fu2016 ER -